Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

Exclusion Criteria

• •Prior transplant within 100 days
• •Radioimmunotherapy within 12 weeks
• •Known human immunodeficiency virus (HIV) or hepatitis B positivity or prior progressive multifocal leukoencephalopathy (PML)
• •Active infection or other medical condition which would preclude treatment in the opinion of the principal investigator; this would include a corrected diffusing capacity of the lungs for carbon monoxide (DLCO) of \< 60% predicted or symptomatic interstitial lung disease
• •Eastern Cooperative Oncology Group (ECOG) performance status \> 2
• •Known active central nervous system (CNS) involvement
• •Peripheral neuropathy \> grade 1 if due to brentuximab vedotin or any peripheral neuropathy \> grade 2
• •Intolerance to brentuximab vedotin
• •Concurrent use of other anti-cancer agents or experimental treatments
• •No current or prior autoimmune disease with the exception of vitiligo and autoimmune alopecia (Arm B only)
• •Pregnancy or breastfeeding; (females of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin \[beta-hCG\] pregnancy test result within 7 days prior to the first dose of brentuximab vedotin; females with false positive results and documented verification that the patient is not pregnant are eligible for participation; females of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy; females of childbearing potential and males who have partners of childbearing potential must agree to use 2 effective contraceptive methods during the study and for 6 months following the last dose of brentuximab vedotin or 6 months following the last dose of nivolumab, whichever is later)